Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Adicet Bio, Inc. (Nasdaq: ACET) announced the cancellation of its proposed public offering of 4,500,000 shares, previously planned due to unfavorable market conditions. The company emphasized its strong financial position, with sufficient capital to meet goals into 2022. CEO Chen Schor highlighted anticipated milestones, including filing INDs for gamma delta CAR-T therapies and initiating Phase 1 studies for non-Hodgkin's lymphoma and other conditions. The company continues to focus on developing innovative allogeneic gamma delta T cell therapies for cancer treatments.
Adicet Bio, a clinical-stage biotechnology company, announced an underwritten public offering of 4,500,000 shares of its common stock, with a potential additional 675,000 shares option for underwriters. The offering, subject to market conditions, aims to raise capital for advancing its gamma delta T cell therapies for cancer treatment. BofA Securities, Jefferies, and SVB Leerink serve as joint book-running managers. The shares will be sold under a shelf registration statement declared effective by the SEC.
Adicet Bio, Inc. (Nasdaq: ACET) announced the grant of 195,898 non-qualified stock options to Nick Harvey, appointed as Chief Financial Officer on September 16, 2020. This option aims to incentivize Mr. Harvey's employment, vesting over four years. The first 25% will vest after one year, with the remaining 75% vesting monthly. Adicet focuses on allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response through engineered T cells.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Nick Harvey as its new Chief Financial Officer. Harvey brings over 20 years of experience in financial operations and capital markets, having previously served at Centrexion Therapeutics and Radius Health, where he played a key role in its IPO. The company's leadership expressed confidence that Harvey's expertise will support Adicet's strategic growth and advancement of its gamma delta T cell therapy platform.
Adicet Bio (Nasdaq: ACET) announced that CEO Chen Schor will present at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 8:40 AM ET. A live audio webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
The company specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing immune responses with engineered T cells for better tumor targeting.